Archives: 2026-09-09

Stem Cell Delivery Approach Shows Promise for Stroke Recovery

A review led by University of Miami researchers examines how delivering stem cells directly into brain-supplying arteries could support recovery after ischemic stroke and identifies the evidence still needed before the approach becomes part of standard care. Key Takeaways Researchers from the University of Miami Miller School of Medicine and collaborating institutions have published a

Read More


Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III Relapsing Multiple Sclerosis trials

Novartis announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.1 Remibrutinib, a highly selective and potent oral Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions with a favorable safety profile. The results of the REMODEL trials establish remibrutinib

Read More